| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amphetamine | 51 | 2022 | 101 | 9.860 |
Why?
|
| Nucleus Accumbens | 55 | 2022 | 113 | 9.380 |
Why?
|
| Central Nervous System Stimulants | 30 | 2020 | 233 | 5.890 |
Why?
|
| Motor Activity | 46 | 2018 | 323 | 4.840 |
Why?
|
| Dopamine | 32 | 2022 | 276 | 4.380 |
Why?
|
| Ventral Tegmental Area | 19 | 2022 | 46 | 3.000 |
Why?
|
| Rats | 76 | 2022 | 4072 | 2.330 |
Why?
|
| Rats, Sprague-Dawley | 50 | 2022 | 1245 | 2.100 |
Why?
|
| Nicotine | 12 | 2021 | 208 | 1.820 |
Why?
|
| Conditioning, Operant | 12 | 2020 | 68 | 1.770 |
Why?
|
| Behavior, Addictive | 9 | 2021 | 137 | 1.660 |
Why?
|
| Substance-Related Disorders | 8 | 2020 | 441 | 1.650 |
Why?
|
| Locomotion | 11 | 2017 | 145 | 1.620 |
Why?
|
| Receptors, Dopamine D1 | 7 | 2017 | 34 | 1.620 |
Why?
|
| Receptors, AMPA | 8 | 2017 | 67 | 1.600 |
Why?
|
| Self Administration | 26 | 2018 | 76 | 1.590 |
Why?
|
| Behavior, Animal | 18 | 2016 | 390 | 1.560 |
Why?
|
| Cocaine | 9 | 2022 | 79 | 1.540 |
Why?
|
| Receptors, Metabotropic Glutamate | 11 | 2008 | 50 | 1.530 |
Why?
|
| Nicotinic Agonists | 6 | 2013 | 73 | 1.530 |
Why?
|
| Drug-Seeking Behavior | 5 | 2018 | 12 | 1.460 |
Why?
|
| Glutamic Acid | 7 | 2022 | 147 | 1.340 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 4 | 2013 | 24 | 1.290 |
Why?
|
| Reinforcement Schedule | 8 | 2018 | 16 | 1.260 |
Why?
|
| Animals | 94 | 2022 | 28155 | 1.220 |
Why?
|
| Rats, Long-Evans | 16 | 2018 | 49 | 1.210 |
Why?
|
| Dopamine Uptake Inhibitors | 6 | 2011 | 43 | 1.150 |
Why?
|
| Morphine | 13 | 2012 | 128 | 1.000 |
Why?
|
| Cues | 6 | 2016 | 186 | 0.990 |
Why?
|
| Saccharin | 3 | 2018 | 9 | 0.970 |
Why?
|
| Reward | 7 | 2013 | 209 | 0.940 |
Why?
|
| Dendritic Spines | 3 | 2016 | 16 | 0.900 |
Why?
|
| Microinjections | 16 | 2017 | 68 | 0.880 |
Why?
|
| Cyclin-Dependent Kinase 5 | 2 | 2014 | 13 | 0.860 |
Why?
|
| Receptors, Dopamine D2 | 4 | 2017 | 57 | 0.800 |
Why?
|
| Gambling | 2 | 2020 | 168 | 0.800 |
Why?
|
| Male | 78 | 2022 | 44557 | 0.790 |
Why?
|
| Uncertainty | 2 | 2020 | 78 | 0.730 |
Why?
|
| Central Nervous System Sensitization | 2 | 2020 | 10 | 0.730 |
Why?
|
| Neostriatum | 2 | 2012 | 23 | 0.700 |
Why?
|
| Amphetamine-Related Disorders | 3 | 2018 | 29 | 0.700 |
Why?
|
| Motivation | 6 | 2013 | 310 | 0.660 |
Why?
|
| Neurons | 10 | 2016 | 1582 | 0.630 |
Why?
|
| Receptors, Nicotinic | 5 | 2013 | 132 | 0.570 |
Why?
|
| Signal Transduction | 4 | 2016 | 3502 | 0.550 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2016 | 37 | 0.550 |
Why?
|
| Mesencephalon | 3 | 2004 | 68 | 0.520 |
Why?
|
| Dopaminergic Neurons | 3 | 2018 | 30 | 0.520 |
Why?
|
| Protein Kinase C | 2 | 2016 | 261 | 0.520 |
Why?
|
| Amphetamines | 3 | 2010 | 18 | 0.510 |
Why?
|
| Benzazepines | 8 | 2017 | 65 | 0.500 |
Why?
|
| Dopamine Agonists | 4 | 2011 | 27 | 0.500 |
Why?
|
| Dopamine Agents | 2 | 2017 | 32 | 0.490 |
Why?
|
| Tegmentum Mesencephali | 8 | 1994 | 12 | 0.460 |
Why?
|
| Cytoskeleton | 1 | 2016 | 198 | 0.450 |
Why?
|
| Time Factors | 14 | 2017 | 5410 | 0.440 |
Why?
|
| Excitatory Amino Acid Agonists | 3 | 2004 | 43 | 0.440 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 2017 | 111 | 0.430 |
Why?
|
| Corpus Striatum | 2 | 2012 | 83 | 0.430 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2017 | 216 | 0.420 |
Why?
|
| Phosphorylation | 7 | 2017 | 1133 | 0.420 |
Why?
|
| Cell Membrane | 1 | 2017 | 664 | 0.410 |
Why?
|
| Nervous System | 1 | 2014 | 92 | 0.400 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2017 | 1914 | 0.390 |
Why?
|
| Microdialysis | 6 | 2009 | 23 | 0.380 |
Why?
|
| Association | 1 | 2012 | 5 | 0.380 |
Why?
|
| Space Perception | 1 | 2013 | 112 | 0.370 |
Why?
|
| Excitatory Amino Acid Antagonists | 5 | 2008 | 79 | 0.360 |
Why?
|
| Up-Regulation | 3 | 2013 | 730 | 0.360 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2014 | 603 | 0.360 |
Why?
|
| Benzoates | 4 | 2000 | 33 | 0.350 |
Why?
|
| Sweetening Agents | 1 | 2011 | 17 | 0.350 |
Why?
|
| Casein Kinase Idelta | 1 | 2011 | 2 | 0.350 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2018 | 176 | 0.350 |
Why?
|
| Glycine | 4 | 2000 | 93 | 0.340 |
Why?
|
| Hyperkinesis | 3 | 2008 | 14 | 0.340 |
Why?
|
| Analysis of Variance | 7 | 2017 | 884 | 0.340 |
Why?
|
| Conditioning, Classical | 3 | 2022 | 38 | 0.330 |
Why?
|
| Ethanol | 3 | 2018 | 273 | 0.320 |
Why?
|
| Dopamine Antagonists | 6 | 2004 | 33 | 0.320 |
Why?
|
| Psychotropic Drugs | 1 | 2011 | 82 | 0.320 |
Why?
|
| Dronabinol | 1 | 2011 | 58 | 0.320 |
Why?
|
| Excitatory Postsynaptic Potentials | 3 | 2017 | 86 | 0.310 |
Why?
|
| Photic Stimulation | 1 | 2012 | 509 | 0.310 |
Why?
|
| Impulsive Behavior | 1 | 2013 | 290 | 0.310 |
Why?
|
| Dendrites | 2 | 2009 | 97 | 0.310 |
Why?
|
| Aggression | 1 | 2013 | 330 | 0.300 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 2 | 2010 | 10 | 0.300 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2006 | 98 | 0.290 |
Why?
|
| Central Nervous System Agents | 1 | 2008 | 15 | 0.280 |
Why?
|
| Amino Acids | 3 | 2006 | 249 | 0.280 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2017 | 307 | 0.260 |
Why?
|
| Drug Administration Schedule | 6 | 2006 | 829 | 0.260 |
Why?
|
| Indoles | 1 | 2009 | 303 | 0.260 |
Why?
|
| Leptin | 2 | 2017 | 100 | 0.260 |
Why?
|
| Behavior | 1 | 2007 | 85 | 0.260 |
Why?
|
| Quinpirole | 2 | 2005 | 7 | 0.250 |
Why?
|
| Avoidance Learning | 1 | 2006 | 21 | 0.250 |
Why?
|
| Brain | 4 | 2013 | 2391 | 0.250 |
Why?
|
| Gene Expression | 2 | 2010 | 1301 | 0.240 |
Why?
|
| Environment | 3 | 2018 | 230 | 0.240 |
Why?
|
| Association Learning | 1 | 2006 | 38 | 0.240 |
Why?
|
| Receptors, Dopamine | 4 | 2000 | 32 | 0.230 |
Why?
|
| Brain Chemistry | 3 | 2007 | 120 | 0.230 |
Why?
|
| Septal Nuclei | 3 | 1990 | 10 | 0.220 |
Why?
|
| Discrimination Learning | 2 | 2016 | 63 | 0.210 |
Why?
|
| Cocaine-Related Disorders | 1 | 2005 | 40 | 0.210 |
Why?
|
| Injections, Intraperitoneal | 5 | 2009 | 102 | 0.210 |
Why?
|
| Purines | 2 | 2014 | 91 | 0.210 |
Why?
|
| Exploratory Behavior | 2 | 2001 | 48 | 0.200 |
Why?
|
| Prefrontal Cortex | 4 | 2009 | 149 | 0.200 |
Why?
|
| Extinction, Psychological | 3 | 2012 | 21 | 0.200 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2003 | 87 | 0.200 |
Why?
|
| Receptors, Glutamate | 1 | 2003 | 22 | 0.190 |
Why?
|
| Mental Disorders | 1 | 2007 | 455 | 0.190 |
Why?
|
| Presynaptic Terminals | 2 | 2012 | 41 | 0.190 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 2 | 2001 | 4 | 0.190 |
Why?
|
| Rats, Inbred Strains | 11 | 1992 | 304 | 0.190 |
Why?
|
| Drug Interactions | 4 | 2006 | 239 | 0.180 |
Why?
|
| Peptide Fragments | 1 | 2003 | 470 | 0.180 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2001 | 6 | 0.170 |
Why?
|
| Humans | 16 | 2021 | 93515 | 0.170 |
Why?
|
| Oxidopamine | 3 | 1998 | 9 | 0.160 |
Why?
|
| Gene Transfer Techniques | 2 | 2010 | 154 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 2 | 2017 | 502 | 0.150 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2017 | 43 | 0.130 |
Why?
|
| Raclopride | 1 | 2017 | 3 | 0.130 |
Why?
|
| Channelrhodopsins | 1 | 2017 | 9 | 0.130 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2017 | 24 | 0.130 |
Why?
|
| Miniature Postsynaptic Potentials | 1 | 2017 | 6 | 0.130 |
Why?
|
| Tobacco Use Disorder | 2 | 2009 | 121 | 0.130 |
Why?
|
| Post-Synaptic Density | 1 | 2017 | 7 | 0.130 |
Why?
|
| Optogenetics | 1 | 2017 | 46 | 0.130 |
Why?
|
| Transduction, Genetic | 1 | 2017 | 160 | 0.130 |
Why?
|
| Luminescent Proteins | 1 | 2017 | 141 | 0.130 |
Why?
|
| Anesthetics, Local | 1 | 2017 | 83 | 0.130 |
Why?
|
| Tissue Culture Techniques | 1 | 2017 | 81 | 0.120 |
Why?
|
| Subcellular Fractions | 1 | 2016 | 88 | 0.120 |
Why?
|
| Carbazoles | 1 | 2016 | 31 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2016 | 66 | 0.120 |
Why?
|
| Naltrexone | 1 | 1997 | 139 | 0.120 |
Why?
|
| Narcotic Antagonists | 1 | 1997 | 170 | 0.110 |
Why?
|
| Point Mutation | 1 | 2016 | 238 | 0.110 |
Why?
|
| Adenylyl Cyclases | 3 | 2011 | 105 | 0.110 |
Why?
|
| Psychomotor Performance | 1 | 1998 | 497 | 0.110 |
Why?
|
| Synapses | 2 | 2014 | 274 | 0.110 |
Why?
|
| Central Nervous System Depressants | 1 | 2014 | 45 | 0.110 |
Why?
|
| Cycloleucine | 3 | 1998 | 10 | 0.100 |
Why?
|
| Synaptic Transmission | 2 | 2012 | 223 | 0.100 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2014 | 75 | 0.100 |
Why?
|
| HEK293 Cells | 1 | 2016 | 696 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 1996 | 492 | 0.100 |
Why?
|
| Appetitive Behavior | 2 | 2006 | 14 | 0.100 |
Why?
|
| Spinal Puncture | 1 | 2013 | 38 | 0.100 |
Why?
|
| Limbic System | 2 | 2012 | 25 | 0.100 |
Why?
|
| Housing, Animal | 1 | 2013 | 51 | 0.100 |
Why?
|
| Narcotics | 2 | 2011 | 72 | 0.100 |
Why?
|
| GABAergic Neurons | 1 | 2013 | 19 | 0.100 |
Why?
|
| Neurotransmitter Agents | 1 | 2013 | 102 | 0.090 |
Why?
|
| Dextroamphetamine | 2 | 1994 | 108 | 0.090 |
Why?
|
| Suicidal Ideation | 1 | 2013 | 75 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2012 | 6 | 0.090 |
Why?
|
| Immunoblotting | 1 | 2013 | 273 | 0.090 |
Why?
|
| Long-Term Potentiation | 1 | 2013 | 51 | 0.090 |
Why?
|
| Pimozide | 2 | 1989 | 3 | 0.090 |
Why?
|
| Extracellular Space | 2 | 2003 | 88 | 0.090 |
Why?
|
| Selegiline | 1 | 1992 | 1 | 0.090 |
Why?
|
| Linear Models | 1 | 2013 | 413 | 0.090 |
Why?
|
| Evoked Potentials, Visual | 1 | 2012 | 90 | 0.090 |
Why?
|
| Serotonergic Neurons | 1 | 2011 | 5 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 502 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 641 | 0.090 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2011 | 20 | 0.090 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 878 | 0.090 |
Why?
|
| Apomorphine | 1 | 2011 | 8 | 0.090 |
Why?
|
| Drug Synergism | 2 | 2002 | 315 | 0.090 |
Why?
|
| Cerebral Cortex | 3 | 2009 | 578 | 0.080 |
Why?
|
| Raphe Nuclei | 1 | 2011 | 37 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 349 | 0.080 |
Why?
|
| Protein Isoforms | 1 | 2011 | 295 | 0.080 |
Why?
|
| CREB-Binding Protein | 1 | 2010 | 16 | 0.080 |
Why?
|
| Dicarboxylic Acids | 2 | 2001 | 24 | 0.080 |
Why?
|
| Threonine | 1 | 2010 | 33 | 0.080 |
Why?
|
| Thionucleotides | 1 | 2010 | 54 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 2495 | 0.080 |
Why?
|
| Aspartic Acid | 1 | 2010 | 66 | 0.080 |
Why?
|
| Parkinson Disease | 1 | 1992 | 175 | 0.080 |
Why?
|
| Pyrrolidines | 2 | 2001 | 61 | 0.080 |
Why?
|
| Substantia Nigra | 1 | 1989 | 27 | 0.080 |
Why?
|
| Simplexvirus | 1 | 2010 | 66 | 0.080 |
Why?
|
| Serine | 1 | 2010 | 105 | 0.080 |
Why?
|
| Cyclic AMP | 1 | 2010 | 276 | 0.070 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 2 | 2003 | 11 | 0.070 |
Why?
|
| Benzylamines | 1 | 2008 | 17 | 0.070 |
Why?
|
| Heroin Dependence | 1 | 1988 | 16 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1799 | 0.070 |
Why?
|
| Heroin | 1 | 1988 | 14 | 0.070 |
Why?
|
| Enkephalins | 1 | 1987 | 14 | 0.070 |
Why?
|
| Female | 7 | 2021 | 48702 | 0.070 |
Why?
|
| Injections, Intravenous | 2 | 2001 | 212 | 0.070 |
Why?
|
| Complement Factor B | 1 | 2007 | 9 | 0.070 |
Why?
|
| Complement Pathway, Alternative | 1 | 2007 | 13 | 0.070 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2007 | 11 | 0.070 |
Why?
|
| Methamphetamine | 1 | 2008 | 104 | 0.060 |
Why?
|
| Spatial Behavior | 1 | 1987 | 20 | 0.060 |
Why?
|
| Injections | 3 | 1994 | 124 | 0.060 |
Why?
|
| Xanthenes | 1 | 2006 | 22 | 0.060 |
Why?
|
| Taste | 1 | 2006 | 29 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2008 | 331 | 0.060 |
Why?
|
| Models, Animal | 1 | 2007 | 282 | 0.060 |
Why?
|
| Pregnancy | 3 | 2018 | 3147 | 0.060 |
Why?
|
| Choice Behavior | 1 | 1987 | 159 | 0.060 |
Why?
|
| Glutamates | 2 | 2008 | 84 | 0.060 |
Why?
|
| Indans | 2 | 2008 | 37 | 0.060 |
Why?
|
| Neuronal Plasticity | 1 | 2007 | 194 | 0.060 |
Why?
|
| Body Temperature Regulation | 1 | 1985 | 59 | 0.060 |
Why?
|
| Salicylamides | 1 | 2004 | 2 | 0.050 |
Why?
|
| Opioid-Related Disorders | 1 | 2007 | 233 | 0.050 |
Why?
|
| Receptors, Kainic Acid | 1 | 2003 | 13 | 0.050 |
Why?
|
| Autoreceptors | 1 | 2003 | 2 | 0.050 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2003 | 26 | 0.050 |
Why?
|
| Homovanillic Acid | 1 | 2003 | 35 | 0.050 |
Why?
|
| Halorhodopsins | 1 | 2022 | 6 | 0.050 |
Why?
|
| Genes, Immediate-Early | 1 | 2002 | 17 | 0.050 |
Why?
|
| Mutation | 1 | 2014 | 4272 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2002 | 20 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 1985 | 0.040 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2001 | 2 | 0.040 |
Why?
|
| Rats, Inbred F344 | 1 | 2021 | 160 | 0.040 |
Why?
|
| Time | 1 | 2001 | 79 | 0.040 |
Why?
|
| Young Adult | 1 | 2013 | 6930 | 0.040 |
Why?
|
| 2-Amino-5-phosphonovalerate | 1 | 2000 | 11 | 0.040 |
Why?
|
| Forecasting | 1 | 2001 | 293 | 0.040 |
Why?
|
| Quinolines | 1 | 2001 | 85 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 2 | 2014 | 378 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 3476 | 0.040 |
Why?
|
| Electric Stimulation | 2 | 2014 | 344 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 2014 | 948 | 0.040 |
Why?
|
| Arousal | 1 | 2000 | 171 | 0.040 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 1 | 2018 | 2 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 401 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 1998 | 19 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 5899 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 87 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2018 | 522 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2000 | 569 | 0.030 |
Why?
|
| Mice | 3 | 2022 | 12269 | 0.030 |
Why?
|
| Individuality | 1 | 1997 | 114 | 0.030 |
Why?
|
| Adrenergic Agents | 1 | 2014 | 6 | 0.030 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2014 | 41 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 2544 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 137 | 0.030 |
Why?
|
| Premedication | 1 | 1994 | 57 | 0.030 |
Why?
|
| Naloxone | 2 | 1985 | 72 | 0.030 |
Why?
|
| Biophysics | 1 | 2014 | 153 | 0.030 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 1994 | 8 | 0.030 |
Why?
|
| Diffusion | 1 | 1994 | 90 | 0.030 |
Why?
|
| Adult | 1 | 2013 | 27918 | 0.030 |
Why?
|
| Micromanipulation | 1 | 1993 | 6 | 0.020 |
Why?
|
| Dialysis | 1 | 1993 | 23 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 1762 | 0.020 |
Why?
|
| Research Design | 1 | 1996 | 617 | 0.020 |
Why?
|
| Infusions, Intraventricular | 1 | 2012 | 5 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1996 | 1922 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2011 | 121 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1990 | 68 | 0.020 |
Why?
|
| Sulpiride | 1 | 1989 | 2 | 0.020 |
Why?
|
| Isoquinolines | 1 | 1989 | 57 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 1990 | 126 | 0.020 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2009 | 120 | 0.020 |
Why?
|
| Bicuculline | 1 | 2007 | 18 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 438 | 0.020 |
Why?
|
| Hormone Antagonists | 1 | 2007 | 19 | 0.020 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 1987 | 21 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 1987 | 57 | 0.020 |
Why?
|
| Complement C3d | 1 | 2007 | 6 | 0.020 |
Why?
|
| Receptors, Opioid | 1 | 1987 | 23 | 0.020 |
Why?
|
| Corticosterone | 1 | 2007 | 35 | 0.020 |
Why?
|
| Punishment | 1 | 2007 | 10 | 0.020 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2007 | 36 | 0.020 |
Why?
|
| Receptors, Opioid, mu | 1 | 1987 | 49 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2007 | 59 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2007 | 32 | 0.020 |
Why?
|
| Complement C3 | 1 | 2007 | 58 | 0.020 |
Why?
|
| Mifepristone | 1 | 2007 | 51 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2007 | 53 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 2007 | 88 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2007 | 162 | 0.020 |
Why?
|
| Restraint, Physical | 1 | 1987 | 31 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2007 | 132 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2007 | 228 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 411 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2009 | 914 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2007 | 147 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2007 | 405 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2008 | 384 | 0.010 |
Why?
|
| Action Potentials | 1 | 2009 | 581 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 366 | 0.010 |
Why?
|
| Metergoline | 1 | 1985 | 1 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2007 | 246 | 0.010 |
Why?
|
| Phenoxybenzamine | 1 | 1985 | 15 | 0.010 |
Why?
|
| Receptors, Adrenergic | 1 | 1985 | 14 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 887 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 464 | 0.010 |
Why?
|
| Receptors, Serotonin | 1 | 1985 | 34 | 0.010 |
Why?
|
| Receptors, Cholinergic | 1 | 1985 | 75 | 0.010 |
Why?
|
| Stereotaxic Techniques | 1 | 1985 | 83 | 0.010 |
Why?
|
| Quantitative Trait Loci | 1 | 2008 | 630 | 0.010 |
Why?
|
| Fever | 1 | 1985 | 122 | 0.010 |
Why?
|
| Hippocampus | 1 | 2007 | 452 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2007 | 513 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2007 | 2850 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2007 | 2121 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 3435 | 0.010 |
Why?
|
| Apoptosis | 1 | 2007 | 1721 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 2484 | 0.010 |
Why?
|
| Dioxanes | 1 | 1994 | 1 | 0.010 |
Why?
|
| Prazosin | 1 | 1994 | 8 | 0.010 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1994 | 30 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1994 | 169 | 0.010 |
Why?
|
| Reaction Time | 1 | 1994 | 317 | 0.010 |
Why?
|
| Hydroxydopamines | 1 | 1990 | 7 | 0.010 |
Why?
|
| Isoproterenol | 1 | 1990 | 57 | 0.010 |
Why?
|
| Denervation | 1 | 1990 | 25 | 0.000 |
Why?
|
| Nerve Fibers | 1 | 1990 | 40 | 0.000 |
Why?
|
| Afferent Pathways | 1 | 1990 | 63 | 0.000 |
Why?
|
| Cerebellum | 1 | 1990 | 248 | 0.000 |
Why?
|